Antioxidant therapy prevents devastating vision loss when added to standard-of-care on rare birth defect

February 5, 2018 by Ellen Goldbaum, University at Buffalo
Light microscopy images of retinas from animal model of Smith-Lemli-Opitz Syndrome (SLOS). Treatment with antioxidant combination therapy (right) preserved normal retinal structure and prevented degeneration and death of photoreceptor cells (rods and cones). Credit: Steven Fliesler

A new study led by vision researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that the addition of widely available antioxidants to the current standard-of-care prevented vision loss in an animal model of a rare genetic disease.

Published in the Jan. 19 issue of Scientific Reports, the paper describes the that resulted in preventing the that can occur in babies born with Smith-Lemli-Opitz Syndrome (SLOS).

Caused by the body's inability to make cholesterol, the disease is a birth defect that results in multiple neurosensory and cognitive abnormalities, physical deformities and disabilities, including . In severe cases, it can be fatal.

"Using our combination therapy approach, we were able to prevent otherwise progressive and irreversible retinal degeneration from occurring in a of this hereditary human metabolic disease that we had previously developed," said Steven J. Fliesler, Ph.D., Meyer H. Riwchun Endowed Chair Professor, vice chair and director of research in the Department of Ophthalmology at the Jacobs School and Ira G. Ross Eye Institute Vision Research Center, and professor in the Department of Biochemistry and Neuroscience Program. He also is a research career scientist at the VA Western New York Healthcare System.

To treat the condition, dietary supplementation with cholesterol is prescribed in addition to treating the individual conditions seen in babies with SLOS, ranging from those affecting the central nervous system (including the eyes) to the heart, lungs, gastrointestinal tract and genitourinary systems, as well as the musculoskeletal . However, Fliesler noted that outcomes from the supplementation vary widely.

"We hypothesized – based upon findings in the literature, including seminal work from my lab – gthat oxidation of a specific molecule (which happens to be the immediate precursor of cholesterol) was key to the disease mechanism," he explained. "We reasoned that blocking the oxidation with antioxidants should prevent or significantly reduce the severity of the retinal degeneration observed in the rodent model. That evidence-based, therapeutic approach worked."

The success of the approach suggests a similar type of combination therapy might also be effective with humans, but Fliesler cautioned that while promising, these results should not be extrapolated directly to humans.

"It is advisable to conduct additional preclinical studies using appropriate animal models of the , such as those we used in this study, in order to refine dosages and specific antioxidant combinations," he said. "Some emerging, highly potent antioxidants not yet approved for human use might in the future be appropriate to investigate a potential treatment for human SLOS patients."

Explore further: First proteomic analysis of birth defect demonstrates power of a new technique

Related Stories

First proteomic analysis of birth defect demonstrates power of a new technique

September 11, 2013
The first proteomic analysis of an animal model of a rare, sometimes deadly birth defect, Smith-Lemli-Opitz Syndrome (SLOS), has revealed that the molecular mechanisms that cause it are more complex than previously understood. ...

Scientist models Smith-Lemli-Opitz syndrome in adult stem cells

April 20, 2016
Studies performed by a Sanford Research scientist using an innovative stem-cell model for a fatal developmental disorder is the focus of a recent study published in Nature Medicine. Kevin Francis, Ph.D. uncovered unique cellular ...

Oxidative stress on the brain

August 24, 2017
Smith-Lemli-Opitz syndrome (SLOS) is a rare disease that occurs when patients inherit from both parents defects in the Dhcr7 gene, which encodes the last enzyme in the cholesterol biosynthesis pathway. A large portion of ...

Fruit fly breakthrough may help human blindness research

December 18, 2017
For decades, scientists have known that blue light will make fruit flies go blind, but it wasn't clear why. Now, a Purdue University study has found how this light kills cells in the flies' eyes, and that could prove a useful ...

New model for hard-to-study form of blindness paves way for future research

September 6, 2017
Macular degeneration is the leading cause of vision loss in older adults, but scientists have long struggled to study and replicate key elements of the disease in the lab. A study published in the Proceedings of the National ...

Gene therapy slows vision loss in mouse models of retinal degeneration

March 24, 2015
Researchers have developed an antioxidant gene therapy that slows cone-cell death and prolongs vision in mouse models of retinal degeneration.

Recommended for you

Eyepatch with dissolvable needles used to treat eye disease

November 12, 2018
A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases. In their paper published in the journal Nature Communications, the ...

Calcifications in the eye increase risk for progression to advanced AMD by more than six times

November 8, 2018
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD). Experts from Queen's University Belfast, working in partnership with the University of Alabama of Birmingham ...

Traditional glaucoma test can miss severity of disease

November 8, 2018
The most common tests for glaucoma can underestimate the severity of the condition by not detecting the presence of central vision loss, according to a new Columbia University study.

New contact lens to treat eye injuries

November 5, 2018
A new therapeutic contact lens that acts as a bandage for eye surface injuries being developed by QUT researchers could soon fast track the healing of previously difficult to treat corneal wounds.

New study offers hope for patients suffering from a rare form of blindness

November 1, 2018
A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia ...

Biologists use 'mini retinas' to better understand connection between eye and brain

October 25, 2018
IUPUI biologists are growing 'mini retinas' in the lab from stem cells to mimic the growth of the human retina. The researchers hope to use the research to restore sight when critical connections between the eye and the brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.